Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹7,896 Cr revenue.
COGS 39.9%, employees 18.3%.
“grew 20.”
“Low to mid teens growth rate compounded is what we will aspire for...tracking slightly ahead of 13% growth guidance”
“300 to 400 basis point improvement in EBITDA margin profile over 3-5 years, roughly 100 bps improvement year on year”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 18.3%▲ | 10.5% |
| ROCE | 23.5%▲ | 13.8% |
| Net Margin | 9.8%▲ | 8.7% |
| EBITDA Margin | 19.7%▲ | 16.0% |
| Debt To Equity | 0.28x▲ | 0.21x |
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹8,850 Cr +12.1% | ₹7,896 Cr |
| Other Income | ₹13 Cr -80.5% | ₹67 Cr |
| Total Income | ₹8,863 Cr +11.3% | ₹7,963 Cr |
| COGS | ₹3,546 Cr +12.7% | ₹3,147 Cr |
| ₹7,605 Cr +8.9% | ₹6,982 Cr | |
| Profit Before Tax | ₹1,207 Cr +24.2% | ₹971 Cr |
| Exceptional Items | (₹52 Cr) -401.3% | (₹10 Cr) |
| ₹312 Cr +18.2% | ₹264 Cr | |
| Net Profit | ₹895 Cr +26.5% | ₹707 Cr |
| Profit (Owners) | ₹870 Cr +27.7% | ₹681 Cr |
| Minority Interest | ₹25 Cr -4.9% | ₹26 Cr |
| Other Comprehensive Income | ₹162 Cr +412.9% | ₹31 Cr |
| EPS | ₹45.89 | ₹35.96 |
| Diluted Shares | ₹19 Cr | ₹19 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Intimation of schedule of Analyst/ Investor Meeting(s) on May 27, 2026
Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Emcure Pharmaceuticals Limited has informed the Exchange about General Updates
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG Rating
Revised intimation of Change in Management with minor correction in cover letter
Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company and Mr. Satish Mehta as Managing Director of the Company
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Recommendation of Final Dividend for the Financial Year 2025-26
Outcome of the Board Meeting held on May 05, 2026.
Emcure Pharmaceuticals Limited has informed the Exchange about General Updates
Emcure Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot
Emcure Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.